臨床検査58巻9号

2014年09月発行

今月の特集1 関節リウマチ診療の変化に対応する

関節リウマチの理解と診療の変遷

著者： 的塲謙一郎¹ 奥田恭章¹

所属機関： ¹道後温泉病院リウマチセンター

ページ範囲：P.998 - P.1003

●関節リウマチ（RA）は全身性炎症疾患である．

●早期診断治療の重要性が増している．

●早期診断に有用となる新たな分類基準が作成された．

●治療はメトトレキサートを中心に，早期より強力に行われる．

●さまざまな合併症を有する疾患であり，治療時には注意が必要である．

参考文献

1）Van Doornum S, McColl G, Wicks IP：Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum　46：862-873，2002

2）Pincus T, Callahan LF：Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. J Rheumatol　13：841-845，1986

3）Arnett FC, Edworthy SM, Bloch DA, et al：The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum　31：315-324，1988

4）Aletaha D, Neogi T, Silman AJ, et al：2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum　62：2569-2581，2010

5）Nagasawa H, Kameda H, Sekiguchi N, et al：Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. Clin Exp Rheumatol　28：365-372，2010

6）Tanaka Y：Next stage of RA treatment : is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis　72（Suppl 2）：ii124-ii127, 2013

7）Tanaka Y：Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol　24：319-326，2012

8）Jayakumar K, Norton S, Dixey J, et al：Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford)　51：169-175，2012

9）Emery P, Breedveld FC, Hall S, et al：Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET) : a randomised, double-blind, parallel treatment trial. Lancet　372：375-382，2008

10）O’Dell JR：Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum　46：283-285，2002

11）Smolen JS, Aletaha D, Bijlsma JW, et al：Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis　69：631-637，2010

12）Nannini C, Ryu JH, Matteson EL：Lung disease in rheumatoid arthritis. Curr Opin Rheumatol　20：340-346，2008

13）Kelly C, Saravanan V：Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother　9：3221-3230，2008

14）Okuda Y, Takasugi K：Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum　54：2997-3000，2006

15）Okuda Y, Ohnishi M, Matoba K, et al：Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol　24：137-143，2014

16）Book C, Saxne T, Jacobsson LT：Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol　32：430-434，2005

17）Young A, Koduri G, Batley M, et al：Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford)　46：350-357，2007

18）Sokka T, Abelson B, Pincus T：Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol　26（5 Suppl 51）：S35-S61，2008

19）Nakajima A, Inoue E, Tanaka E, et al：Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol　39：360-367，2010